| Title |
Comprehensive lung injury pathology induced by mTOR inhibitors
|
|---|---|
| Published in |
Clinical and Translational Oncology, August 2009
|
| DOI | 10.1007/s12094-009-0394-y |
| Pubmed ID | |
| Authors |
Guadalupe Aparicio, Moisés B. Calvo, Vanessa Medina, Ovidio Fernández, Paula Jiménez, Martina Lema, Angélica Figueroa, Luis M. Antón Aparicio |
| Abstract |
Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibroproliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Germany | 1 | 5% |
| Unknown | 17 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 26% |
| Student > Ph. D. Student | 4 | 21% |
| Student > Bachelor | 3 | 16% |
| Other | 2 | 11% |
| Professor | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 2 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 37% |
| Agricultural and Biological Sciences | 5 | 26% |
| Biochemistry, Genetics and Molecular Biology | 3 | 16% |
| Chemistry | 1 | 5% |
| Unknown | 3 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#4,765,602
of 23,056,273 outputs
Outputs from Clinical and Translational Oncology
#203
of 1,322 outputs
Outputs of similar age
#18,043
of 91,507 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 6 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,322 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 91,507 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them